2021
Signature of an exclusive licensing agreement with Université Laval regarding the use and development of proprietary and patented blood biomarkers for Parkinson’s disease.
2022
Signature as an industry and financial partner regarding an academic grant to Dr. Cicchetti from le ministère de l’Économie, de l’Innovation et de l’Énergie (MEI-Quebec Gouvernent).
2023
Completion of a drug development plan with the support of a group of experts and consultants regarding a novel formulation of cysteamine called SYN-001 best suited to meet the clinical needs in Parkinson’s disease.
2024
Signature of an agreement and financial support with the Quebec Consortium for Drug Discovery (CQDM) and University of Laval for the development of SYN-001.
